European Geriatric Medicine - Supplement 1 - Volume 7 - October 2016

62 / 290

individuals in Europe. The project will advance understanding by
bringing together longitudinal studies across cities in Europe to
unravel the causal pathways and multi-level interactions between the
urban environment and psychosocial and biological determinants of
mental health and cognitive function in older adults.
Expected Results: The geriatric perspective within MINDMAP
stresses the importance of early detection of pre-clinical stages of
frailty, including mental aspects, as a core component of functional
competence among older persons. The Functional Ability Index
developed in the Longitudinal Urban Cohort Ageing Study will be
applied. Considering both resources and risk factors will enable the
identification of target groups for early prevention, and for clinical
interventions [1].
Key conclusions: Knowledge will significantly contribute to future-
proof preventive strategies in urban settings favouring the mental
dimension of healthy ageing, the reduction of the negative impact of
mental disorders on co-morbidities, and maintaining cognitive ability
in old age.
Funding: European Union, Horizon 2020 Programme (667661)
Reference
[1] Dapp U. et al. BMC Geriatrics 2014;14:141.
P-105
From nature to the elderly: Salvia sclareoides as a source of
bioactive compounds against Alzheimer’ s disease
C. Dias1, T. Jorge1, P. Madeira1, F. Marcelo2, J. Jimenez-Barbero2,
C. Airoldi3, F. Nicotra3, P. Davis4, R. Staniforth4, A.P. Rauter1. 1CQB/DQB,
Faculdade de Ciências, Universidade de Lisboa, Portugal; 2Centro de
Investigaciones Biológicas, CSIC, Madrid, Spain; 3Department of
Biotechnology and Biosciences, University of Milano-Bicocca, Italy;
4Department of Molecular Biology and Biotechnology, University of
Sheffield, Sheffield, UK
Alzheimer’ s disease is one of the most common types of dementia
causing deep economic and social impacts. Salvia sclareoides is a non-
toxic iberian endemic plant that has been studied in our research
group targeting both cholinergic system and amyloid cascade [1]. Our
studies showed that S. sclareoides extracts are potent inhibitors
of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) [1].
In order to recognize the compounds responsible for this activity,
STD-NMR experiments of the crude plant extracts were performed
and rosmarinic acid was found as the only explicit binder for AChE.
Furthermore, it was possible to give for the first time insights into
the 3D structure model of the rosmarinic acid-AChE complex, allowing
to propose a new binding site in AChE [2]. On the other hand,
S. sclareoides has also been studied in our group for its ability to
prevent amyloid fibril formation. Salvia extracts were able to
destabilize pre-formed cystatin B fibrils, and STD-NMR showed once
again that rosmarinic acid was the only explicit binder for A β1-42
peptide oligomers. Interestingly, caffeic acid, a smaller unit of
rosmarinic acid, revealed to retain the same activity in remodeling
A β oligomerization [3]. In addition, envisioning the bioavailability
enhancement of these products and the physico-chemical charac-
teristics of carbohydrates/amyloid interaction, a series of rosmarinic
glycosylated analogues is currently under development. Our work
demonstrates that S. sclareoides is a resourceful and promising plant
to act as a dual target nutraceutical towards neurodegenerative
diseases. Moreover, it can provide inspiration for further drug
development towards new disease modifying agents.
References
1. Rauter A. P., Branco I., Lopes R. G., Justino J., Silva F. V. M., Noronha
J., Cabrita E. J., Brouard I., Bermejo J. Fitoterapia, 78, 474, 2007.
2. Marcelo F., Dias C., Martins A., Madeira P. J., Jorge T., Florêncio
M. H., Cañada F. J., Cabrita E. J., Jimenez-Barbero J., Rauter A. P.
Chem. Eur. J. 19, 6641, 2013.
3. Airoldi C., Sironi E., Dias C., Marcelo F., Martins A., Rauter A. P.,
Nicotra F., Jimenez-Barbero J. Chem. Asian J. 8, 596, 2013.
P-106
Progression of Alzheimer’ s disease. A longitudinal, case control
study in Norwegian memory clinics
R.S. Eldholm1, K. Persson2,3 , M.L. Barca2,3, A.-B. Knapskog2,3,
H. Kersten2, K. Engedal2, G. Selbæk2,4, I. Saltvedt1. 1Department of
Neuroscience, Norwegian University of Science and Technology (NTNU),
Trondheim, 2Norwegian National Advisory Unit on Ageing and Health,
Vestfold Hospital Trust, Tønsberg, 3Department of Geriatric Medicine,
Memory Clinic, Oslo University Hospital, Oslo; 4Research Centre for Old
Age Psychiatric Research, Innlandet Hospital Trust, Ottestad, Norway
Introduction: The disease progression rate in Alzheimer’ s disease
(AD) varies considerably between individuals. There is lack of evidence
of the underlying factors behind these differences. The overall aim of
this study is to examine factors of importance for disease progression
in AD.
Methods: The Progression of Alzheimer’s Disease and Resource use
(PADR) study is a longitudinal case-control observational study
conducted in Norwegian memory clinics. A comprehensive assess-
ment was performed at baseline and follow up after 18– 28 months.
Progression rate was measured by change in the Clinical Dementia
Rating Sum of Boxes (CDR-SB). Dementia and Alzheimer’ s disease was
diagnosed according to the ICD-10 criteria and MCI according to the
Winblad criteria. Patients with amnestic MCI (aMCI) were counted as
AD patients for analyses.
Results: The AD group (n = 282) consists of 105 patients with aMCI and
177 AD patients with dementia. Mean age was 73.3 (8.8) years, 50,5%
were females, they had 12.1 ± 3.7 years of education and baseline score
on MMSE 23.7 ± 4.4 points. The overall progression rate for the AD
patients in CDR-SB was 1.59 points/year (95% confidence interval [CI]:
1.38–1.80).
Key conclusions: The progression rate we found is comparable to the
declinemeasured in similar studies. Later analysis in PADRwill focus at
associations between concomitant cardiovascular disease and vascu-
lar risk factors, depression, MRI findings, inflammation and drug use
and disease progression. The study will contribute to further knowl-
edge about factors influencing the progression rate.
P-107
Association between micronutrients and preserved cognitive
functions over a nine-year period in older adults: the Invecchiare In
Chianti study
M. Fedecostante1, S. Bandinelli 2, P. Eusebi3, M. Colpo2, A. Cherubini1.
1Italian National Research Center on Aging, Ancona, 2Geriatric Unit, Local
Health Unit–Tuscany Centre (LHUTC), Florence, 3Epidemiology
Department, Regional Health Authority of Umbria, Perugia, Italy
Introduction: Evidence suggest that various micronutrients could
delay the onset of age-associated cognitive decline and dementia. Our
study aims at investigating the association between plasma levels of
specific micronutrients and cognitive health over a nine-year period in
a large sample of older adults enrolled in the InCHIANTI study.
Methods: Longitudinal study of 1073 non-demented adults aged 65
years or older from the InChianti study. Cognitive health was defined
as an improvement, stability or a reduction of no more than 1 point in
the MMSE score. Mixed-effects regression models were used to
analyze the role of several factors in predicting negative outcomes. A
multinomial response was used in order to investigate factors
associated with cognitive stability by taking into account for mortality
as competing outcome.
Results: Among multiple micronutrients evaluated, only plasma levels
of α-tocopherol (VitE) were associated with cognitive health when
adjusted for possible confounders such as gender, age, smoke, total
cholesterol, triglycerides, and for factors associated with cognitive
health in our analysis such as baseline MMSE, Parkinson’s disease,
ischemic heart disease, hip fracture (OR: 1.05, 95% CI: 1.01– 1.09),
taking into account for mortality as competing outcome.
Poster presentations / European Geriatric Medicine 7S1 (2016) S29–S259 S56